PALLAS: Predictors of early palbociclib discontinuation in patients with early breast cancer

Breast Cancer

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Ann Oncol

Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025

doi: 10.1016/j.annonc.2025.09.007

Breast Cancer

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

Eur J Cancer

Aristei C, Tomatis M, Ponti A, Marotti L, Battisti NML, Leung Cheung K, Hartmann OJ, Rubio IT, Santini D, Sardanelli F, Senkus E, van Dam P, Curigliano G, Eusoma Working Group

doi: 10.1016/j.ejca.2026.116259

Breast Cancer

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study

Eur J Cancer

Louis FM, der Voort AV, Egeler MD, Ramshorst MSV, Mandjes IA, Kemper I, Agterof MJ, der Steeg WAV, Heijns JB, Bekkum MLV, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Peeters MTV, Mann RM, de Poll-Franse LVV, Sonke GS, Dutch Breast Cancer Research Group (BOOG)

doi: 10.1016/j.ejca.2026.116882

Breast Cancer

24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial

Breast

Güth U, Hoefnagels N, Müller A, Schär S, Rosset L, Nobahar Corke M, Schwitter M, Jakob A, Balmelli C, Leo C, Fehr M, Thorn DR, Riniker S, Chouiter-Djebaili A, Musilova J, Ribi K, Honecker F, Swiss Cancer Institute

doi: 10.1016/j.breast.2026.104789

ESMO 2025

Breast Cancer

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

Breast Cancer

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer

Lancet Oncol

Kaidar-Person O, Weltens CG, Fortpied C, Scheijmans LJEE, Kirkove CY, Budach V, Peignaux-Casasnovas K, Valli M, Peters M, van der Leij F, Rivera S, Weidner N, van den Bongard DHJG, Linsenmeier C, Abdah-Bortnyak R, Hosni S, Koiter E, Engelen AM, Baten A, Champezou L, Fourquet A, Bartelink HGMM, Struikmans H, Poortmans PMP, EORTC Radiation Oncology and Breast Cancer Groups

doi: 10.1016/S1470-2045(26)00233-0

SABCS 2025

Breast Cancer

DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer

Lung, Respiratory and Thoracic Cancer

Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer

Lung Cancer

Brascia D, Mangiameli G, Congedo MT, Mastromarino MG, Catelli C, Schiavon M, Giudici V, Senatore A, Bonis A, Lucchi M, Luzzi L, Magaritora S, Rea F, Marulli G

doi: 10.1016/j.lungcan.2026.108946

Breast Cancer

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer

Clin Cancer Res

Dieci MV, Gasparini E, Nicolè L, Schmid P, Zambelli A, Favaretto A, Piacentini F, Bianchi GV, Mion M, Ferro A, Arpino G, Emiliani A, Cinieri S, Zamagni C, Gennari A, Spazzapan S, Sartori D, Zustovich F, Tamberi S, Del Mastro L, De Laurentiis M, Musolino A, Cagossi K, Generali D, Giarratano T, Giovanardi F, De Salvo GL, Conte P, Guarneri V

doi: 10.1158/1078-0432.CCR-26-0975

Related content

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study

24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer

DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer

Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer